Aymeric Sallin - 02 Jan 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Reporting relationship: Director
Issuer ticker: RNAC
Reported as of: 02 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jan 2024, 17:07:20 UTC
Prior SEC filing: 15 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Aymeric Sallin

Key filing fact

Aymeric Sallin filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 04 Jan 2024.

Key facts

This page summarizes Aymeric Sallin's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Jan 2024, 17:07.

Change

Previous filing in this sequence was filed on 15 Nov 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNAC transaction

Common Stock

Award

Transaction value: $0
Shares: +178,000
Change %
Price: $0.000000
Shares after: 178,000
Date: 02 Jan 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNAC transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +228,000
Change %
Price: $0.000000
Shares after: 228,000
Date: 02 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 228,000
Exercise price: $0.6552
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments so that the underlying shares will be fully vested on January 2, 2027.

Footnote F2

This award will vest in 36 equal monthly installments, so that it shall be fully vested on January 2, 2027.